Search

Your search keyword '"Marc L. Citron"' showing total 51 results

Search Constraints

Start Over You searched for: Author "Marc L. Citron" Remove constraint Author: "Marc L. Citron" Topic medicine.medical_specialty Remove constraint Topic: medicine.medical_specialty
51 results on '"Marc L. Citron"'

Search Results

1. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)

2. Exploration of communication gaps among women with metastatic breast cancer, caregivers and oncologists

3. Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

4. Understanding the Needs of Patients with Metastatic Breast Cancer: Results of the Make Your Dialogue Count Survey

5. Abstract P1-11-06: The experience of caregivers of women with metastatic breast cancer: Insights from the Make Your Dialogue Count survey

6. Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715)

7. Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer

8. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)

9. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

10. Abstract P2-15-03: Cardiac safety of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (EBC): Final data from TDM4874g

11. Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy

12. Isolated Sternal Involvement in Breast Cancer: Is it Truly Stage IV Disease?

13. Is there a role for older-patient-specific cancer clinical trials? A pooled analysis of 2277 older patients in adjuvant breast cancer trials (Alliance A151715)

14. Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives

15. Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience

16. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)

17. Dose Density in Adjuvant Chemotherapy for Breast Cancer

18. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

19. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

20. Dihydro-5-azacytidine in malignant mesothelioma

21. Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice?

22. A Phase II Trial of Concomitant Human Interleukin-2 and Interferon-??-2a in Patients with Disseminated Malignant Melanoma

23. Phase II Trial of High-Dose 24-Hour Continuous Intravenous 5-Fluorouracil for Advanced Non-Small Cell Lung Cancer: A Cancer and Leukemia Group B Study

24. Emotional experiences of oncologists treating women with metastatic breast cancer (MBC)

25. Doctor-patient perceptions and discourse on side effects related to metastatic breast cancer (MBC) treatment: The Make Your Dialogue Count survey

26. Lung Cancer Risk in White and Black Americans

27. 413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy–Results From CALGB/Intergroup 9741

28. The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer

29. Understanding potential communication gaps between oncologists and patients with advanced breast cancer: A survey of oncologists

30. Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB 9741 (Alliance)

31. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281

32. Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer

33. 5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin

34. O6-methylguanine-DNA methyltransferase in normal and malignant tissue of the breast

35. Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience

36. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer

37. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG

38. Dose-Dense Chemotherapy for Node-Positive Breast Cancer

40. Placebos and Principles: A Trial of Ondansetron

41. O6-Methylguanine-DNA Methyltransferase in ovarian malignancy and its correlation with postoperative response to chemotherapy

42. Lung Cancer, Tuberculin Reactivity, and Isoniazid

43. Hickman Catheter Tip Displacement

44. Intramedullary spinal cord metastases treated by complete resection of tumor prior to radiotherapy and chemotherapy. Case report and review

45. Modulation of human tumor colony growth in soft agar by serum

46. Risks in Antiemesis Using Dexamethasone

47. Pneumococcal-vaccine-induced thrombocytopenia

48. Patient-Controlled Analgesia for Severe Cancer Pain

49. Superior Vena Cava Syndrome due to Non—Small-cell Lung Cancer

50. Treatment of Superior Vena Cava Syndrome-Reply

Catalog

Books, media, physical & digital resources